Answers are grounded in this paper and cite their sources.
Demonstrates that BDNF-loaded neural stem cell exosomes suppress microglial activation and promote neurogenesis in a rat stroke model, highlighting their potential as targeted nanocarriers.
JOURNAL/nrgr/04.03/01300535-202302000-00042/figure1/v/2026-05-26T054653Z/r/image-tiff Our previous study demonstrated the potential therapeutic role of human neural stem cell-derived exosomes (hNSC-Exo) in ischemic stroke. Here, we loaded brain-derived neurotrophic factor (BDNF) into exosomes derived from NSCs to construct engineered exosomes (BDNF-hNSC-Exo) and compared their effects with those of hNSC-Exo on ischemic stroke both in vitro and in vivo . In a model of H 2 O 2 -induced oxidative stress in NSCs, BDNF-hNSC-Exo markedly enhanced cell survival. In a rat middle cerebral artery occlusion model, BDNF-hNSC-Exo not only inhibited the activation of microglia, but also promoted the differentiation of endogenous NSCs into neurons. These results suggest that BDNF can improve the function of NSC-derived exosomes in the treatment of ischemic stroke. Our research may support the clinical use of other neurotrophic factors for central nervous system diseases.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: